biorasi Blogs

41. Commonalities Of Rare Diseases 5/2/2019

    Along with a fear of a low ROI, pharmaceutical companies have been hesitant to take on rare disease drug development because the indications can be challenging to study. Although each rare disease is unique, some elements of the clinical operations of rare disease trials are consistent across indications. Here are some common challenges experienced during the course of researching rare diseases.

42. The Current Standing Of Research On Stem Cell Therapies For Wound Healing 5/2/2019

    Wound healing is a complicated and dynamic process that includes multiple overlapping phases. To control costs and improve outcomes for wound-care patients, researchers are turning to regenerative medicine; specifically, stem cell therapy. Read more about the types of stem cells and how they assist with wound healing.

43. The Future Of Diabetes Treatment 5/1/2019

    For those of us who are living with or who have a family member living with type 1 diabetes, we are probably well acquainted with the promises of pancreas transplants, islet stem cell therapy, and other science fiction. But what types of advances can we realistically hope for in the next 5 to 10 years? Or maybe even in the next 2 years?

44. A Deep Dive Into NASH Physiology And Drug Targets 5/1/2019

    One of the problems with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been a lack of understanding of the basic science. Up until the past few years, the treatment approach outside of changing lifestyle factors (i.e. diet and exercise) has been to repurpose old drugs that were used for metabolic syndrome or type 2 diabetes, since these diseases overlap in many ways. By continuing to study the basic science behind the disease and the drugs designed to treat it so that better, more specific drugs may be developed in the future.

45. How Managers Can Establish Good Working Relationships With Their Internal Team 5/1/2019

    A team is only as successful as its leadership, and leading successfully and gracefully is both an art and a science; a title does not make a manager. Following are some of the qualities a strong manager will have.

46. Considerations For Working With Research-Naive vs. Experienced Sites 5/1/2019

    Some sites have a lot of experience, and those are generally sought after, but they can be busy running other trials and may not prioritize yours. It may be beneficial to include less experienced sites in order to have better chances of enrolling. But of course, there are some necessary considerations when turning to these sites.

47. Why Aren't There Any FDA-Approved Drugs To Treat NASH? 5/1/2019

    No drugs have been approved by the FDA to treat NAFLD or NASH. Fortunately, there are some promising studies being conducted right now with numerous companies invested in the race. Why is there such a large gap to fill in this indication?

48. You're Holding Your Eye Drops Wrong – What Makes Ophthalmology Trials So Challenging? 4/30/2019

    Recently, one of our resident experts in ophthalmology, Ignacio Handal, gave a training for some of our current studies with a focus on which pitfalls to avoid specifically in ophthalmology trials. He dished out many fun facts and eye-opening insights.

49. A More Complete Scope For Advances in Women's Health 4/30/2019

    The field of medicine pertaining to women’s health is rapidly growing to include the study of both specific conditions that only manifest in women and also maintenance of well-being and quality of life during the unique but normal life cycles experienced by women. Fortunately, we are beginning to understand the implications of women-specific needs on mental and emotional health, and new devices are being designed to cater to these needs.

50. The Politics of Investigator-Initiated Trials 4/30/2019

    IITs present a way for post-marketing, real-world data to be added to a drug or device’s portfolio without the sponsor initiating the research. Everyone can agree on the fact that more research, and especially real world evidence, is helpful for advancing the field of medicine, but not everyone is always in favor of IITs. Following are problems and benefits of IITs.